# GLP-1 Policy Watch: Insurance, Compounding, and FDA Updates > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/glp-1-insurance-coverage-update-policy-watch/ > **Published:** 2026-04-16T11:43:57-04:00 | **Last Modified / Clinically Audited:** 2026-06-21T23:58:53-04:00 > **Clinical Summary:** Stay informed on the latest GLP-1 insurance coverage update and policy developments affecting clinical prescribing and patient access in 2026. --- #### Clinical Takeaway Key GLP-1 policy developments affecting clinical prescribing and [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/). GLP-1 Policy Watch April 16, 2026 - **GLP-1 [Insurance Coverage](https://cedclinic.com/workers-compensation-medical-cannabis-chronic-pain-coverage/) Update: April 16, 2026**As of April 2026, twelve states mandate GLP-1 coverage for obesity, though commercial insurers and Medicare Part D plans often restrict access without diabetes diagnosis, requiring clinicians to verify formulary status.Source: CMS / Formulary Tracker - **Compounding GLP-1 Medications: Regulatory Status as of April 16, 2026**The FDA maintains semaglutide shortage status, permitting continued compounding while clinicians monitor weekly updates; tirzepatide compounding regulations differ and require separate verification.Source: FDA Drug Shortage Database - **Prior Authorization Burden for GLP-1 Prescriptions: April 16, 2026**CMS proposes expedited prior authorization standards for GLP-1 medications to reduce 11-day processing delays and 30% denial rates, improving timely access for diabetic and obese patients.Source: American Medical Association [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) RELATED READING AT CED CLINIC Continue exploring the evidence [Medicare Covers CBD Without FDA Approval and Faces a Lawsuit](https://cedclinic.com/medicare-cbd-policy-regulatory-access/) Explore Medicare coverage challenges and regulatory updates related to CBD, relevant to understanding insurance dynamics for GLP-1 therapies. [Read More](https://cedclinic.com/medicare-cbd-policy-regulatory-access/) [Policy Watch: 16 Regulatory Updates — March 13, 2026](https://cedclinic.com/cannabis-medicine-regulations-2026-march-13-updates/) Stay updated on recent [regulatory changes](https://cedclinic.com/texas-hemp-regulatory-changes-2026-thc-product-rules/) impacting medical therapies, including compounding and insurance policies. [Learn More](https://cedclinic.com/cannabis-medicine-regulations-2026-march-13-updates/) [CMS Finalizes CY 2027 Medicare Advantage and Part D Rule | Insights](https://cedclinic.com/medicare-advantage-payment-rate-increase-2027/) Understand upcoming Medicare Advantage and Part D rule changes that affect coverage and prior authorization for medications like GLP-1. [Discover Insights](https://cedclinic.com/medicare-advantage-payment-rate-increase-2027/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=GLP-1%20Policy%20Watch%3A%20Insurance%2C%20Compounding%2C%20and%20FDA%20Updates&url=https%3A%2F%2Fcedclinic.com%2Fglp-1-insurance-coverage-update-policy-watch%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fglp-1-insurance-coverage-update-policy-watch%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=GLP-1%20Policy%20Watch%3A%20Insurance%2C%20Compounding%2C%20and%20FDA%20Updates%20https%3A%2F%2Fcedclinic.com%2Fglp-1-insurance-coverage-update-policy-watch%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).